Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Total Current Liabilities (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Total Current Liabilities for 7 consecutive years, with $13.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 18.15% to $13.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.0 million, a 18.15% increase, with the full-year FY2025 number at $13.0 million, up 18.15% from a year prior.
  • Total Current Liabilities was $13.0 million for Q4 2025 at Fulcrum Therapeutics, up from $11.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $22.6 million in Q1 2021 to a low of $8.1 million in Q1 2025.
  • A 5-year average of $15.2 million and a median of $14.5 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: soared 61.44% in 2021, then plummeted 33.08% in 2023.
  • Fulcrum Therapeutics' Total Current Liabilities stood at $19.2 million in 2021, then decreased by 12.89% to $16.7 million in 2022, then decreased by 18.24% to $13.7 million in 2023, then dropped by 19.24% to $11.0 million in 2024, then rose by 18.15% to $13.0 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Total Current Liabilities are $13.0 million (Q4 2025), $11.6 million (Q3 2025), and $9.0 million (Q2 2025).